Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
A Phase II Study(A)over-cap of Sequential Pembrolizumab (PEM)(A)over-cap Followed(A)over-cap By AVD for Frontline Treatment(A)over-cap of Classical Hodgkin Lymphoma (CHL): Quantifying Response Following(A)over-cap PEM Monotherapy(A)over-cap with FDG-PLT-Derived Metabolic Tumor Volume and Total Lesion Glycolysis Savas, H., Allen, P., Evens, A. M., Pro, B., Dillehay, G., Rademaker, A., Palmer, B., Advani, R., Gordon, L. I., Winter, J. N. AMER SOC HEMATOLOGY. 2018
View details for DOI 10.1182/blood-2018-99-113836
View details for Web of Science ID 000454837605028